Related references
Note: Only part of the references are listed.FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Naval Daver et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
Esperanza Such et al.
BLOOD (2013)
Clonal architecture of chronic myelomonocytic leukemias
Raphael Itzykson et al.
BLOOD (2013)
Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
Sophie Park et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Raphael Itzykson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
An evolutionary perspective on chronic myelomonocytic leukemia
R. Itzykson et al.
LEUKEMIA (2013)
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
F. Damm et al.
LEUKEMIA (2013)
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
R. R. Laborde et al.
LEUKEMIA (2013)
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
M. M. Patnaik et al.
LEUKEMIA (2013)
Treatment of chronic myelomonocytic leukemia with azacitidine
Eric Wong et al.
LEUKEMIA & LYMPHOMA (2013)
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study
Luana Fianchi et al.
LEUKEMIA & LYMPHOMA (2013)
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
Lionel Ades et al.
LEUKEMIA RESEARCH (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review
Michael Thorpe et al.
LEUKEMIA RESEARCH (2012)
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature
Rahel A. Mathew et al.
LEUKEMIA RESEARCH (2012)
Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: Novel Pathogenetic Lesions
Hideki Muramatsu et al.
SEMINARS IN ONCOLOGY (2012)
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities
Hesham Eissa et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
Anna M. Jankowska et al.
BLOOD (2011)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun et al.
BLOOD (2011)
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia
Ulrike Bacher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Activity of Azacitidine in Chronic Myelomonocytic Leukemia
Rubens Costa et al.
CANCER (2011)
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Esperanza Such et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance
V. Grossmann et al.
LEUKEMIA (2011)
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
O. Abdel-Wahab et al.
LEUKEMIA (2011)
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
Alexander E. Smith et al.
BLOOD (2010)
Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
P. Krishnamurthy et al.
BONE MARROW TRANSPLANTATION (2010)
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
Veronique Gelsi-Boyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms
Thomas Ernst et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
Alexander Kohlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis H. Grand et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Outcome of allo-SCT for chronic myelomonocytic leukemia
S. Ocheni et al.
BONE MARROW TRANSPLANTATION (2009)
Therapy related CMML: a case report and review of the literature
Faheem Ahmed et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies
Hideki Makishima et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML
A. Tefferi et al.
LEUKEMIA (2009)
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
Veronique Gelsi-Boyer et al.
BMC CANCER (2008)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
E. J. Feldman et al.
LEUKEMIA (2008)
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
P. W. Wijermans et al.
LEUKEMIA RESEARCH (2008)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:: evidence from a core dataset of 2124 patients
Detlef Haase et al.
BLOOD (2007)
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes
Timo Siitonen et al.
HAEMATOLOGICA (2007)
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
Ahmed Aribi et al.
CANCER (2007)
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M. D. Anderson prognostic scoring system
Miloslav Beran et al.
LEUKEMIA & LYMPHOMA (2007)
Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology
Attilio Orazi et al.
MODERN PATHOLOGY (2006)
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia
Alfonso Quintas-Cardama et al.
CANCER (2006)
Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature
K. B. Kim et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2006)
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia
M Elliott et al.
BONE MARROW TRANSPLANTATION (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information
U Bacher et al.
ANNALS OF HEMATOLOGY (2005)
Chronic Myelomonocytic Leukemia: lost in classification?
DT Bowen
HEMATOLOGICAL ONCOLOGY (2005)
Risk assessment in chronic myelomonocytic leukemia (CMML)
U Germing et al.
LEUKEMIA & LYMPHOMA (2004)
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia
P Mittal et al.
BONE MARROW TRANSPLANTATION (2004)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
JF Apperley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia.: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
F Onida et al.
BLOOD (2002)
Dysplastic versus proliferative CMML -: a retrospective analysis of 91 patients from a single institution
T Nösslinger et al.
LEUKEMIA RESEARCH (2001)
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes
A Venditti et al.
ANNALS OF HEMATOLOGY (2000)
Share Paper
